Pomalidomide-PEG1-azide is primarily utilized in the development of targeted cancer therapies, particularly in the field of proteolysis-targeting chimeras (PROTACs). Its structure allows for the conjugation of pomalidomide, a known immunomodulatory agent, with other molecules via the azide group, enabling the creation of bifunctional compounds. These compounds can selectively degrade disease-causing proteins by leveraging the ubiquitin-proteasome system. Additionally, the PEG1 spacer enhances solubility and stability, making it suitable for use in drug delivery systems. This chemical is also employed in bioconjugation and click chemistry applications, facilitating the attachment of various functional groups or biomolecules for research and therapeutic purposes.